OMAHA, Neb., Aug. 6, 2018 /PRNewswire/ -- A modern genetic test for a cancer patient contains more information than ever before: Too much, in fact, for modern digital medical records.
That's a problem. A big, big data problem. But it's a problem with a solution at the University of Nebraska Medical Center.
New tests, particularly those genetic cancer tests, hold critical clues about the nature and ferocity of a tumor. They help doctors and patients plan treatments, and adjust for new mutations in the tumor.

Ad Statistics
Times Displayed: 50203
Times Visited: 1423 Ampronix, a Top Master Distributor for Sony Medical, provides Sales, Service & Exchanges for Sony Surgical Displays, Printers, & More. Rely on Us for Expert Support Tailored to Your Needs. Email info@ampronix.com or Call 949-273-8000 for Premier Pricing.
But those tests don't neatly fit into modern health records. In fact, those test results don't fit at all. Physicians must wade through multiple file attachments, or scroll through an apparently never-ending "notes" section for the important details.
It's like looking for a specific movie scene among a stack of old VHS tapes. That's great for 1995, but not in today's digital age that moves at warp speed.
The problem is that electronic health records—EHR for short—were originally created to help the billing process.
"EHRs were not built for clinical teams to use as searchable databases," said Kelly Choi, M.D., GenomOncology's Chief Commercial Officer. GenomOncology is a Cleveland-based firm focused specifically on all that biomedical data, or informatics that comes out of cancer gene testing and research.
GenomOncology builds powerful engines that doctors and researchers use to tease important information from things like complex genetic tests. After signing an exclusive agreement with UNMC, GenomOncology now has a way to transmit those results to a patient's EHR, arming their doctors and care-providers with a clearer picture of their patient's health and history.
"Most in the industry thought it wasn't possible to pass genomic data in a discrete manner with the current infrastructure, but we were able to find a way, with the team at UNMC," said Manuel Glynias, founder and CEO of GenomOncology.
The deal began with UNMC researchers Scott Campbell, Ph.D., and Jim Campbell, M.D., who managed to simplify the complex. They developed a way to codify and name the multitude of facts that come from cancer gene testing. It needed to be something that a doctor could quickly and easily understand.
"There's all this new research about cancer, and none of it matters until you can determine what kind of cancer you have and what to do about it," said Joe Runge, the business development manager at UNMC's technology transfer and commercialization office, UNeMed. "This technology helps doctors more easily integrate all this new information."